Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 9/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510733 | 0.91 | KCNH2 (0.53) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14110712 | 0.89 | NR1I2 (0.49) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL3928566 | 0.88 | KCNH2 (0.63) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4492772 | 0.88 | KCNH2 (0.63) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14567253 | 0.87 | KCNH2 (0.64) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4853581 | 0.85 | NR1I2 (0.54) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14567261 | 0.83 | NR1I2 (0.55) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13936719 | 0.83 | NR1I2 (0.51) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13841676 | 0.82 | NR1I2 (0.49) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13936937 | 0.81 | KCNH2 (0.63) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399758-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-15 | — | — | US | disclosed |
| US-20070060565-A1 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060565-A1 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | ZC3HAV1, CYP3A5, SLC10A1 | NR1I2 201/4885KCNH2 934/4885CYP3A4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.